小鼠 体内IFNAR-1阻断抗体,体外IFNAR-1阻断抗体

小鼠 体内IFNAR-1阻断抗体,体外IFNAR-1阻断抗体

价格: ¥5600

品牌:康宁

货号:BE0241

收藏

产品详情

相关推荐

克隆性 :多克隆

抗体英文名 :InVivoMAb anti-mouse IFNAR-1

抗体名 :小鼠 体内IFNAR-1阻断抗体,体外IFNAR-1阻断抗体

规格 :5mg

小鼠 体内IFNAR-1阻断抗体,体外IFNAR-1阻断抗体
Bio X Cell抗体优势:
✔ 通过大规模的组织培养生产抗体,亲和层析法纯化抗体,
✔ 所有抗体均具有高纯度(>95%)、低内毒素(<2EU/mg),无防腐剂和稳定剂的特性,适用于体内临床前研究
✔ 所有抗体可提供100mg甚至50g的大包装,性价比非常高
Bio X Cell抗体应用
热销抗体
抗原 应用 克隆号 InVivoMab
目录号
InVivoPlus
目录号
PD-1 体内PD-1/PD-L1信号封闭 RMP1-14 BE0146 BP0146
体内PD-1/PD-L1信号封闭,体外PD-1中和,IHC(冰冻),IF,WB,FC 29F.1A12 BE0273 BP0273
体内PD-1/PD-L1信号封闭,体外PD-1中和,WB J43 BE0033-2 BP0033-2
InVivo rat IgG2a isotype control, PD-1同型对照,排除Fc段与抗原的非特异性结合 2A3 BE0089 BP0089
PD-L1(B7-H1) 体内PD-L1信号封闭,IF,IHC(冰冻),FC,WB 10F.9G2 BE0101 BP0101
InVivo rat IgG2b isotype control, PD-L1同型对照,排除Fc段与抗原的非特异性结合 LTF-2 BE0090 BP0090
CTLA-4 体内 CTLA-4 中和,WB 9D9 BE0164 BP0164
体内和体外中和CTLA-4,WB 9H10 BE0131 BP0131
体内和体外中和CTLA-4,FC,WB UC10-
4F10-11
BE0032 BP0032
NK1.1 体内NK细胞去除,FC PK136 BE0036 BP0036
CD3ε 体内T细胞去除,体外T细胞刺激/激活,IF,FC,WB, 145-2C11 BE0001-1 BP0001-1
CD4 体内CD4+T细胞去除,FC,WB GK1.5 BE0003-1 BP0003-1
CD8α 体内CD8+T细胞去除,IF,FC,WB 53-6.7 BE0004-1 BP0004-1
CD25 (IL-2Rα) 体内调节T细胞去除,FC PC-61.5.3 BE0012 BP0012
CD28 体内CD8封闭,体外T细胞刺激/激活 37.51 BE0015-1 /
体外T细胞刺激/激活 PV-1 BE0015-5 /
CSF1R (CD115) 体内巨噬细胞去除,体外CSF-R1中和,体内单核细胞去除, FC,WB AFS98 BE0213 BP0213
IL-4 体内IL-4中和,体外IL-4中和,体内IL-4受体刺激(as a complex with IL-4)
FC,WB
11B11 BE0045 BP0045
IFNγ (interferon
gamma)
体内IFNγ中和,体外IFNγ中和,ELISPOT,FC,WB XMG1.2 BE0055 BP0055
Ly6G 体内中性粒细胞耗竭,体内MDSC耗尽, IF,IHC(石蜡或冰冻),FC 1A8 BE0075-1 BP0075-1
Ly6G/Ly6C (Gr-1) 体内Gr-1+骨髓细胞去除,IHC(石蜡或冰冻),FC RB6-8C5 BE0075 BP0075
IFNAR-1 体内IFNAR-1阻断,体外IFNAR-1阻断,WB MAR1-5A3 BE0241 BP0241
InVivoMab VS InVivoPlus
- InVivoMab InVivoPlus
纯度 >95% >95%
蛋白完整性 √(SDS-PAGE) √(SDS-PAGE)
内毒素浓度 2EU/mg <1EU/mg
有效性验证(WB/FC/ELISA)
蛋白聚集物<5%
小鼠病原体测试
无叠氮化物和载体蛋白
大批量生产
适用体内研究
目录号 BE开头 BP开头
InVivoPlusTM 系列抗体非常适用于高灵敏性实验以及用活细胞或整个动物进行各种功能测定的体内研究,可加快您的研究进展。

热销同型对照和InVivoPure抗体稀释Buffer
产品类型 品名 用途 InVivoMab
目录号
InVivoPlus
目录号
部分热卖同型
对照
InVivoMab rat IgG2a isotype control 排除一抗的Fc段与
抗原的非特异性结合,
使实验结果更加严谨,
有助于您发表高分论文
BE0089 BP0089
InVivoMab rat IgG2b isotype control BE0090 BP0090
InVivoMab mouse IgG1 isotype control BE0083 BP0083
InVivoMAb human IgG1 isotype control BE0297 BP0297
InVivoPlus rat IgG2a isotype control BE0089 BP0089
InVivoMab mouse IgG2a isotype control BE0085 BP0085
InVivoMabrat IgG1 isotype control BE0088 BP0088
InVivoPlus mouse IgG1 isotype control BE0083 BP0083
InVivoMAb polyclonal Armenian hamster IgG BE0091 BP0091
抗体稀释Buffer InVivoPure pH 7.0 Dilution Buffer 官方指定抗体稀释
buffer,确保抗体使用
性能,加快您的实验进展
IP0070 /
InVivoPure pH 6.5 Dilution Buffer IP0065 /
✔ 为了加快您实验进度,确保实验结果的准确性,建议您搭配使用Bio X Cell一抗对应的同型对照(排除一抗的非特异性结合)和InVivoPure抗体稀释缓冲液。

About InVivoMAb anti-mouse IFNAR-1

The MAR1-5A3 monoclonal antibody reacts with mouse IFNAR-1 (IFN alpha/beta receptor subunit 1). IFNAR-1 is coexpressed with IFNAR-2 on nearly all cell types and together these two subunits make up the heterodimeric Type I IFN Receptor complex. Type I IFNs (IFN-α/β) bind to the Type I IFN Receptor complex to induce cellular responses including induction of anti-viral, anti-microbial, anti-tumor, and autoimmune responses as well as to regulate the activation, proliferation, and differentiation of many cell types. The MAR1-5A3 antibody has been shown to inhibit Type I IFN receptor signaling in vitro and in vivo.

InVivoMAb anti-mouse IFNAR-1 Specifications

Isotype Mouse IgG1, κ
Recommended Isotype Control(s) InVivoMAb mouse IgG1 isotype control, unknown specificity(BE0083)
Recommended InVivoPure Dilution Buffer InVivoPure pH 7.0 Dilution Buffer(IP0070)
Immunogen Extracellular domain of mouse IFNAR-1
Reported Applications
  • in vivo IFNAR-1 blockade
  • in vitro IFNAR-1 blockade
  • Western blot
Endotoxin
  • <2EU/mg (<0.002EU/μg)
  • Determined by LAL gel clotting assay
Purity
  • >95%
  • Determined by SDS-PAGE
Formulation
  • PBS, pH 7.0
  • Contains no stabilizers or preservatives
Sterility 0.2 μM filtered
Production Purified from tissue culture supernatant in an animal free facility
Purification Protein G
Storage The antibody solution should be stored at the stock concentration at 4°C. Do not freeze.
RRID AB_2687723
Molecular Weight 150 kDa

Application References

InVivoMAb anti-mouse IFNAR-1 (Clone: MAR1-5A3)

Macal, M., et al. (2018). "Self-Renewal and Toll-like Receptor Signaling Sustain Exhausted Plasmacytoid Dendritic Cells during Chronic Viral Infection." Immunity 48(4): 730-744 e735. PubMed Although characterization of T cell exhaustion has unlocked powerful immunotherapies, the mechanisms sustaining adaptations of short-lived innate cells to chronic inflammatory settings remain unknown. During murine chronic viral infection, we found that concerted events in bone marrow and spleen mediated by type I interferon (IFN-I) and Toll-like receptor 7 (TLR7) maintained a pool of functionally exhausted plasmacytoid dendritic cells (pDCs). In the bone marrow, IFN-I compromised the number and the developmental capacity of pDC progenitors, which generated dysfunctional pDCs. Concurrently, exhausted pDCs in the periphery were maintained by self-renewal via IFN-I- and TLR7-induced proliferation of CD4(-) subsets. On the other hand, pDC functional loss was mediated by TLR7, leading to compromised IFN-I production and resistance to secondary infection. These findings unveil the mechanisms sustaining a self-perpetuating pool of functionally exhausted pDCs and provide a framework for deciphering long-term exhaustion of other short-lived innate cells during chronic inflammation. Liu, X., et al. (2015). "CD47 blockade triggers T cell-mediated destruction of immunogenic tumors." Nat Med 21(10): 1209-1215. PubMed Macrophage phagocytosis of tumor cells mediated by CD47-specific blocking antibodies has been proposed to be the major effector mechanism in xenograft models. Here, using syngeneic immunocompetent mouse tumor models, we reveal that the therapeutic effects of CD47 blockade depend on dendritic cell but not macrophage cross-priming of T cell responses. The therapeutic effects of anti-CD47 antibody therapy were abrogated in T cell-deficient mice. In addition, the antitumor effects of CD47 blockade required expression of the cytosolic DNA sensor STING, but neither MyD88 nor TRIF, in CD11c(+) cells, suggesting that cytosolic sensing of DNA from tumor cells is enhanced by anti-CD47 treatment, further bridging the innate and adaptive responses. Notably, the timing of administration of standard chemotherapy markedly impacted the induction of antitumor T cell responses by CD47 blockade. Together, our findings indicate that CD47 blockade drives T cell-mediated elimination of immunogenic tumors. Schliehe, C., et al. (2015). "The methyltransferase Setdb2 mediates virus-induced susceptibility to bacterial superinfection." Nat Immunol 16(1): 67-74. PubMed Immune responses are tightly regulated to ensure efficient pathogen clearance while avoiding tissue damage. Here we report that Setdb2 was the only protein lysine methyltransferase induced during infection with influenza virus. Setdb2 expression depended on signaling via type I interferons, and Setdb2 repressed expression of the gene encoding the neutrophil attractant CXCL1 and other genes that are targets of the transcription factor NF-kappaB. This coincided with occupancy by Setdb2 at the Cxcl1 promoter, which in the absence of Setdb2 displayed diminished trimethylation of histone H3 Lys9 (H3K9me3). Mice with a hypomorphic gene-trap construct of Setdb2 exhibited increased infiltration of neutrophils during sterile lung inflammation and were less sensitive to bacterial superinfection after infection with influenza virus. This suggested that a Setdb2-mediated regulatory crosstalk between the type I interferons and NF-kappaB pathways represents an important mechanism for virus-induced susceptibility to bacterial superinfection. Welten, S. P., et al. (2015). "The viral context instructs the redundancy of costimulatory pathways in driving CD8(+) T cell expansion." Elife 4. doi: 10.7554/eLife.07486. PubMed

上海研卉生物科技有限公司

实名认证

金牌会员

入驻年限:10年

联系人:李先生

地址:上海

电话联系

购买咨询

换一个